Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction

被引：1

作者：

Wells, Quinn S. ^{[1
,2
]}

Farber-Eger, Eric ^{[1
,2
]}

Lipworth, Loren ^{[2
,3
]}

Dluzniewski, Paul ^{[4
]}

Dent, Ricardo ^{[4
]}

Umeijiego, John ^{[4
]}

Cohen, Sarah S. ^{[3
,5
]}

机构：

[1] Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Med Ctr, Nashville, TN USA

[2] Vanderbilt Univ, Med Ctr, Vanderbilt Translat & Clin Cardiovasc Res Ctr VTR, Nashville, TN USA

[3] Vanderbilt Univ, Dept Med, Div Epidemiol, Med Ctr, Nashville, TN 37235 USA

[4] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA

[5] Toxstrategies Inc, Epidstrategies, Cary, NC 27511 USA

来源：

CLINICAL EPIDEMIOLOGY | 2022年 / 14卷

关键词：

heart failure; reduced ejection fraction; real-world evidence; electronic health record; RANDOMIZED INTERVENTION TRIAL; CIBIS-II; MORTALITY; ENALAPRIL; SURVIVAL; METOPROLOL; MORBIDITY; OUTCOMES;

D O I：

10.2147/CLEP.S341919

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

li li li Conclusion: Approximately 40% of RW HFrEF patients met criteria for the GALACTICHF trial. While findings of ongoing clinical trials may be directly generalizable to this sizable proportion of patients, future trials should examine whether the majority of patients with lower prevalence of comorbidities and rate of HF hospitalization could benefit from emerging HF treatments.

引用

页码：39 / 49

页数：11

共 50 条

[1] Characteristics and Outcomes of a Real-world Population with Heart Failure with Reduced Ejection Fraction Representative of Clinical Trial Patients
Cohen, Sarah S.
Farber-Eger, Eric
Lipworth, Loren
Umejiego, John
Dent, Ricardo
Dluzniewski, Paul
Wells, Quinn S.
JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S82 - S82
[2] Comparability Of The GALACTIC-HF Clinical Trial Population To Real-world Patients Having Heart Failure With Reduced Ejection Fraction
Mefford, Matthew T.
Koyama, Sandra Y.
De Jesus, Justine
Wei, Rong
Fischer, Heidi
Harrison, Teresa N.
Woo, Pauline
Reynolds, Kristi
JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S11 - S12
[3] Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
Huusko, Jenni
Purmonen, Timo
Toppila, Iiro
Lassenius, Mariann
Ukkonen, Heikki
ESC HEART FAILURE, 2020, 7 (03): : 1039 - 1048
[4] Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study
Hao, Zhengyang
Zhang, Yanzhou
CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2022, 6 (04) : 219 - 223
[5] Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction
Mapelli, Massimo
Salvioni, Elisabetta
de Martino, Fabiana
Mattavelli, Irene
Bonomi, Alice
Sassi, Valentina
Gugliandolo, Paola
Vignati, Carlo
Magini, Alessandra
Rovai, Sara
Paolillo, Stefania
Agostoni, Piergiuseppe
JOURNAL OF CARDIOVASCULAR MEDICINE, 2020, 21 (11) : 882 - 888
[6] Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
Oh, Jaewon
Lee, Chan Joo
Park, Jin Joo
Lee, Sang Eun
Kim, Min-Seok
Cho, Hyun-Jai
Choi, Jin-Oh
Lee, Hae-Young
Hwang, Kyung-Kuk
Kim, Kye Hun
Yoo, Byung-Su
Choi, Dong-Ju
Baek, Sang Hong
Jeon, Eun-Seok
Kim, Jae-Joong
Cho, Myeong-Chan
Chae, Shung Chull
Oh, Byung-Hee
Kang, Seok-Min
ESC HEART FAILURE, 2022, 9 (02): : 1492 - 1495
[7] Patient profiles in heart failure with reduced ejection fraction: Prevalence, characteristics, treatments and outcomes in a real-world heart failure population
Musella, Francesca
Rosano, Giuseppe M. C.
Hage, Camilla
Benson, Lina
Guidetti, Federica
Moura, Brenda
Sibilio, Gerolamo
Boccalatte, Marco
Dahlstrom, Ulf
Coats, Andrew J. S.
Lund, Lars H.
Savarese, Gianluigi
EUROPEAN JOURNAL OF HEART FAILURE, 2023, : 1246 - 1253
[8] Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real-world heart failure population
Musella, F.
Lund, L. H. L. Lars H.
Lina Benson, L. B.
Federica Guidetti, F. G.
Moura, B. M. Brenda
Sibilio, G. S. Gerolamo
Boccalatte, M. B. Marco
Dahlstrom, U. D. Ulf
Coats, A. J. S. C. Andrew J. S.
Rosano, G. M. C. R. Giuseppe M. C.
Savarese, G. S. Gianluigi
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 85 - 86
[9] Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting
Nordberg Backelin, Charlotte
Fu, Michael
Ljungman, Charlotta
ESC HEART FAILURE, 2020, 7 (03): : 1049 - 1055
[10] Sacubitril/Valsartan in heart failure with reduced ejection fraction: clinical and echocardiographic insights from a real world population
Valli, F.
Bursi, F.
Santangelo, G.
Toriello, F.
Rusconi, I.
Mondellini, G.
Vella, A. M.
Faggiano, A.
Persampieri, S.
Carugo, S.
Guazzi, M.
EUROPEAN HEART JOURNAL, 2021, 42 : 785 - 785

← 1 2 3 4 5 →